#None #Medtronic #Galway #Sphere-9 #PulseSelect

Promising Results from Medtronic's Heart Devices at APHRS 2026

Medtronic plc, a major player in healthcare technology, recently showcased significant findings from real-world registries regarding their Sphere-9™ catheter and PulseSelect™ Pulsed Field Ablation (PFA) System during the Asia Pacific Heart Rhythm Society (APHRS) 2026 conference. The results, which focus on treatment methods for patients experiencing atrial fibrillation (AFib) and ventricular tachycardia (VT), highlight Medtronic's commitment to innovation in cardiac ablation technology.

Detailed Insights from the Registry Analyses

In the realm of cardiac care, safety and effectiveness are paramount. Medtronic's APEX global registry standout results underscore this priority. The analysis revealed data from 1,050 AFib patients treated across 28 sites, revealing a remarkably low major complication rate of just 1.1%. Notably, there were no reported cases of acute kidney injury or severe complications such as coronary spasms or nerve injuries, demonstrating the reliability of the Sphere-9 catheter and Affera™ Mapping and Ablation System.

In evaluating results between initial and repeat ablation procedures, the data noted no significant fluctuations in major complication rates, a testament to the technology's consistent performance. Medtronic's focus on optimizing procedures aligns well with enhancing patient safety and overall treatment experiences.

Evaluating the REAL PULSE Registry Findings

In a similar vein, the REAL PULSE global registry provided promising outcomes for the PulseSelect PFA system. This analysis encompassed 1,160 patients globally and reported a remarkable 100% acute success rate, with only 0.09% of those patients experiencing any serious major complications. Such statistics are critical in fostering confidence in these innovative therapeutic options for managing arrhythmias.

Expanding Applications in Ventricular Tachycardia

Additionally, a European APEX registry analyzed the Sphere-9’s performance in addressing ventricular tachycardia. This specific cohort of 46 patients included those with both ischemic and non-ischemic sustained VT. The results were equally encouraging, showing a high acute success rate of 87% and an estimated six-month freedom from VT recurrence at 75%. Importantly, the data indicated no major differences in long-term outcomes between the ischemic and non-ischemic groups, which paves the way for more standardized treatment protocols.

Advocating for Continued Innovation

The noteworthy data shared by Medtronic illustrates the significant strides made in cardiac ablation technologies. Khaldoun Tarakji, M.D., who serves as the Vice President and Chief of Science, Research and Technology at Medtronic, expressed optimism about these results, underscoring the value of real-world evidence in affirming the safety and efficacy of these medical devices. Medtronic remains committed to continuous innovation, ensuring that its technologies not only meet but also exceed the expectations for patient care.

In summary, Medtronic's Sphere-9 catheter and PulseSelect PFA system represent a significant advancement in cardiac ablation technology. With the recent favorable data from the APEX and REAL PULSE registries at APHRS 2026, clinicians and patients alike can anticipate improved outcomes in the treatment of complex arrhythmias. As Medtronic forges ahead in this field, their dedication to transformative healthcare solutions continues to be evident, ensuring that patients receive the most effective and safe interventions possible.

For more information on Medtronic and their range of healthcare solutions, visit their website or follow them on LinkedIn.